Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has grabbed attention from the analysts, when it saw a value increase of 13.73% or 0.14 points in the last trading session to close at $1.16. A total of 3.69 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 548.34 Million shares, while its relative volume stands at 7.46. Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has a market cap of $13.76 Million and the number of outstanding shares have been calculated 11.86 Million.

Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $60 on the stock, this valuation is based on 1 number of opinions. The most optimistic analyst sees the stock reaching $3 while the most conventional has $3 target price.

In order to check on the sell-side rational, we can also take a peek at some technical indicators. Immune Pharmaceuticals Inc. (NASDAQ:IMNP)’s price sits -46.77% off from its 50-day moving average of $1.84 and -61.55% away from the stock’s 200-day moving average which is $1.72. Stock’s twelve month price oscillated between $8.16 and $1.02. The stock hit its twelve month high on 09/07/16, and twelve month low on 08/31/17. The Average True Range, a measure of volatility is at 0.29, however its weekly and monthly volatility is 20.12%, 21.45% respectively. The company’s Relative Strength Index which shows price strength currently stands at 38.16.

Immune Pharmaceuticals Inc. (NASDAQ:IMNP) as of recent trade, has shown weekly downbeat performance of -20% which was maintained at -43.14% in 1-month period. During the past three months the stock slid -48.21%, bringing six months performance to -67.03%. Yearly performance of the stock shows a bearish trend of -82.38% while year-to-date (YTD) performance reflected -68.13% negative outlook.

While taking a glance at financials, we can look at a number of key indicators. Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has trailing twelve month Return on Assets of -163.7%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -844.9% and a Return on Investment of 0%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.

While having a peek at profitability ratios Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.

However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Immune Pharmaceuticals Inc. (NASDAQ:IMNP)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 2.17.

The company’s quick ratio for most recent quarter is 0 along with current ratio for most recent quarter of 0. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.